Announcement on Application Acceptance of Lacosamide Oral Solution Generic Name: Lacosamide Oral Solution Dosage form: Oral solution Registration Category: 5.2 Category Our company and HETERO LABS LIMITED, Indiahasreached a cooperation on Lacosamide Oral Solution in 2019. We are exclusively responsible for the registration and commercialization of this produc...

On April 23rd, Shenzhen Beimei Pharmaceutical Co., Ltd. announced the opening of the first laboratory of the Beimei Pediatric Medicine Development Center.

Our company and HETERO LABS LIMITED of India reached cooperation on Oseltamivir Phosphate for Oral Suspension at the beginning of this year.

On November 26, 2019, Shenzhen Beimei Pharmaceutical Co., Ltd., Registration Department and R & D Department were relocated to the new office area

On June 18, 2019, Shenzhen Beimei Pharmaceutical Co., Ltd. signed a license and cooperation agreement with Hetero, India. High-level officials from both sides celebrated the successful signing of the contract along the beautiful Huangpu River.

Ms. Wu Guangmei, Chairman of Beimei Pharmaceuticals, was appointed by the Global Association of Scientific and Technological Services in Shanghai on June 17, 2019.

At the beginning of the New Year, we have received the contract signed by Indian W Company

20 November 2018,"Clinical Study on Efficacy, Safety and Economics of Sultamicillin for Suspension in the Treatment of Children with Mild to Moderate Acute Bacterial Lower Respiratory Tract Infection"

After nearly half a year's preparation, Shenzhen Beimei Pharmaceutical Co., Ltd. recently officially approved the certification of "Intellectual Property Management System" organized by the state-designated regulatory certification body, and has successfully obtained the certification certificate.